Skip to content

Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02910037
Acronym
PDAID
Enrollment
214
Registered
2016-09-21
Start date
2016-06-01
Completion date
2017-07-31
Last updated
2021-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Encephalitis, Meningitis

Keywords

metagenomic next-generation sequencing, microbiological diagnosis, bacterial infections, viral infections, fungal infections, parasitic infections

Brief summary

This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS) assay to provide a demonstration of precision medicine for diagnosis of acute infectious disease in hospitalized patients. From June 2016 to June 2017, 200 patients will be enrolled from multiple hospitals in California and outside of California. Patients will be evaluated to determine the impact on the mNGS assay on diagnostic yield, hospital costs and clinical outcomes.

Detailed description

This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS) assay to provide a demonstration of precision medicine for diagnosis of acute infectious disease in hospitalized patients, with the goal of directly impacting clinical care and improving patient mortality. This diagnostic test has been previously validated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, the University of California, San Francisco Clinical Microbiology Laboratory. From June 2016 to June 2017, investigators will prospectively enroll 200 patients from multiple hospitals in California (University of California, San Francisco; University of California, Los Angeles; University of California, Davis; Children's Hospital Los Angeles) and outside California (Children's National Medical Center, Children's Hospital Colorado, St. Jude Children's Research Hospital) for mNGS testing, and evaluate the impact on the assay on diagnostic yield, hospital costs and clinical outcomes.

Interventions

This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.

Sponsors

California Initiative to Advance Precision Medicine
CollaboratorOTHER
Sandler Foundation
CollaboratorUNKNOWN
Bowes Foundation
CollaboratorUNKNOWN
Charles and Helen Schwab Foundation
CollaboratorUNKNOWN
University of California, Davis
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
Children's Hospital Los Angeles
CollaboratorOTHER
Children's Hospital Colorado
CollaboratorOTHER
St. Jude Children's Research Hospital
CollaboratorOTHER
Children's National Research Institute
CollaboratorOTHER
University of California, Berkeley
CollaboratorOTHER
DNAnexus, Inc.
CollaboratorUNKNOWN
Syapse, Inc.
CollaboratorUNKNOWN
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Minutes to 110 Years
Healthy volunteers
No

Inclusion criteria

Exclusions: * Patients on a 5150 or 5250 psychiatric hold * Prisoners * University of California employees / students or close associates of any of the key personnel on the study * Outpatients and/or patients with chronic illness Inclusion: Demographic Criteria 1. Age: any (no age limit) 2. Language: any (with the use of interpreting services for obtaining consent) For the following, the infectious syndromes include meningitis, encephalitis, fever, sepsis, and pneumonia: Clinical Criteria 1. Hospital admission or transfer with diagnosis of an presumed infectious syndrome or clinical presentation consisting with an infectious syndrome, as defined below: * Meningitis: fever \>38°C and abnormal imaging or CSF pleocytosis (CSF white blood cell count (WBC) \> 5 /mm\^3) +/- stiff neck, +/- headache, +/- seizure * Encephalitis: pleocytosis and at least one of the following: altered mental status, seizures, new onset of focal neurologic findings, abnormal EEG, acute brain abnormalities on neuroimaging 2. No known diagnosis of non-infectious etiology responsible for symptoms 3. Time of enrollment: within 7 days of onset of symptoms, either initial presentation or acute exacerbation of presumed infectious syndrome. Specimen Criteria 1. cerebrospinal fluid available within 7 days of symptom onset AND within 3 days of hospital admission or transfer unless evidence for acute exacerbation as defined by abrupt decline in clinical status, worsening pleocytosis or other laboratory parameters 2. Minimum of 600 microliters (uL) of clinical sample, stored at 4 degrees Celsius (C) no more than 5 days (ideally frozen in -70 degrees Celsius within 24 hours of collection) 3. No more than 3 freeze-thaw cycles

Design outcomes

Primary

MeasureTime frameDescription
Total Number of Cases With at Least One Provider Responsewithin 1 month of patient enrollment in studyInvestigators will evaluate impact of mNGS assay by clinician surveys and Clinical Microbial Sequencing Board (CMSB) feedback and discussion as measured by at least 1 provider response per case.

Secondary

MeasureTime frameDescription
Clinical Outcomes: Time From Cerebrospinal Fluid Collection to mNGS Resultsfrom admission to 1 month post discharge for each patient during the enrollment period of studyInvestigators will review medical records to determine time of initial presentation and measure the time to mNGS results.
Clinical Outcomes: Length of Stayfrom admission to 1 month post discharge for each patient during the enrollment period of studyInvestigators will review medical records to determine length of stay including discharge to rehab facilities.
Clinical Outcomes: Final Diagnosis Categoryfrom admission to time of final case review (1 month post discharge or up to one year)Investigators will review medical records to determine final diagnosis after all diagnostic testing has been performed including metagenomic Next-Gen sequencing and autopsy where applicable.
Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogensfrom admission to 1 month post discharge for each patient during the enrollment period of studymNGS findings were compared to conventional testing for concordance. Conventional testing included both tests that were ordered as part of each patients workup and those order to confirm mNGS findings on cerebrospinal fluid (CSF).

Countries

United States

Participant flow

Participants by arm

ArmCount
Patients Enrolled for mNGS Testing
Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents). mNGS for pathogen detection: This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
204
Total204

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up6
Overall StudyWithdrawal by Subject4

Baseline characteristics

CharacteristicPatients Enrolled for mNGS Testing
Age, Categorical
<=18 years
45 Participants
Age, Categorical
>=65 years
35 Participants
Age, Categorical
Between 18 and 65 years
124 Participants
Age, Continuous39.6 years
STANDARD_DEVIATION 22.5
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
17 Participants
Race (NIH/OMB)
Black or African American
13 Participants
Race (NIH/OMB)
More than one race
42 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
13 Participants
Race (NIH/OMB)
White
118 Participants
Region of Enrollment
United States
204 participants
Sex: Female, Male
Female
90 Participants
Sex: Female, Male
Male
114 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
23 / 204
other
Total, other adverse events
0 / 204
serious
Total, serious adverse events
0 / 204

Outcome results

Primary

Total Number of Cases With at Least One Provider Response

Investigators will evaluate impact of mNGS assay by clinician surveys and Clinical Microbial Sequencing Board (CMSB) feedback and discussion as measured by at least 1 provider response per case.

Time frame: within 1 month of patient enrollment in study

Population: Treating teams for 204 included patients

ArmMeasureValue (NUMBER)
Pre mNGS Result Feedback From ProvidersTotal Number of Cases With at Least One Provider Response98 cases
Post mNGS Results Feedback From ProvidersTotal Number of Cases With at Least One Provider Response58 cases
Secondary

Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens

mNGS findings were compared to conventional testing for concordance. Conventional testing included both tests that were ordered as part of each patients workup and those order to confirm mNGS findings on cerebrospinal fluid (CSF).

Time frame: from admission to 1 month post discharge for each patient during the enrollment period of study

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Pre mNGS Result Feedback From ProvidersClinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens16 Participants
Post mNGS Results Feedback From ProvidersClinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens174 Participants
NeoplasticClinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens9 Participants
Post InfectiousClinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens1 Participants
Toxic MetabolicClinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens4 Participants
Secondary

Clinical Outcomes: Final Diagnosis Category

Investigators will review medical records to determine final diagnosis after all diagnostic testing has been performed including metagenomic Next-Gen sequencing and autopsy where applicable.

Time frame: from admission to time of final case review (1 month post discharge or up to one year)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Pre mNGS Result Feedback From ProvidersClinical Outcomes: Final Diagnosis Category17 Participants
Post mNGS Results Feedback From ProvidersClinical Outcomes: Final Diagnosis Category57 Participants
NeoplasticClinical Outcomes: Final Diagnosis Category7 Participants
Post InfectiousClinical Outcomes: Final Diagnosis Category3 Participants
Toxic MetabolicClinical Outcomes: Final Diagnosis Category3 Participants
StructuralClinical Outcomes: Final Diagnosis Category0 Participants
VascularClinical Outcomes: Final Diagnosis Category1 Participants
OtherClinical Outcomes: Final Diagnosis Category15 Participants
UnknownClinical Outcomes: Final Diagnosis Category101 Participants
Secondary

Clinical Outcomes: Length of Stay

Investigators will review medical records to determine length of stay including discharge to rehab facilities.

Time frame: from admission to 1 month post discharge for each patient during the enrollment period of study

ArmMeasureValue (MEAN)Dispersion
Pre mNGS Result Feedback From ProvidersClinical Outcomes: Length of Stay27.9 daysStandard Deviation 32.5
Secondary

Clinical Outcomes: Time From Cerebrospinal Fluid Collection to mNGS Results

Investigators will review medical records to determine time of initial presentation and measure the time to mNGS results.

Time frame: from admission to 1 month post discharge for each patient during the enrollment period of study

ArmMeasureValue (MEAN)Dispersion
Pre mNGS Result Feedback From ProvidersClinical Outcomes: Time From Cerebrospinal Fluid Collection to mNGS Results13.5 daysStandard Deviation 4.8

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026